

## Special Issue

# Development of Novel Mucosal Vaccines: Advances in Technology and Delivery

### Message from the Guest Editor

We are pleased to invite you to contribute to this Special Issue, where we aim to focus on pathogens that invade the body through mucosal sites. Examples of this include oral and intranasal vaccination, which have emerged as promising approaches for mucosal vaccine delivery. Technological advancements in mucosal vaccination have heightened immunological responses, simplified administration, and enhanced efficacy. The primary objective of this Special Issue is to describe the latest technological developments that enable the effective delivery of vaccines, specifically focusing on mucosal vaccines and their development, production, processing, and design. Additionally, novel vaccine platforms for mucosal immunization, such as mRNA, DNA, viral vectors, live attenuated bacteria, bacterial vectors, and encapsulation techniques, are of interest. We look forward to receiving your contributions. Best regards,

### Guest Editor

Dr. Mohamed I. Hussein El-Sayed

Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA

### Deadline for manuscript submissions

31 January 2026



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/199921](https://mdpi.com/si/199921)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).